AbbVie Inc. ($ABBV) Stock Forecast: Up 0.0% Today

What is AbbVie Inc.?

AbbVie (ABBV) is a pharmaceutical company recognized for its popular drugs like Humira, Skyrizi, and Rinvoq. The company has seen a recent increase in market value due to strong sales performance of its key products.

Why is AbbVie Inc. going up?

ABBV stock is up 0.0% on Oct 28, 2025 14:40

• AbbVie's recent market upturn is linked to positive market expectations for its upcoming Q3 earnings, with a particular focus on the growth of Skyrizi and Rinvoq.
• Market sentiment remains optimistic about AbbVie's future prospects despite analyst predictions of an earnings decrease, driven by the success of its leading drugs.
• Although the stock saw a slight decline compared to the overall market recently, the company has demonstrated significant growth of over 30% in the last six months, led by robust sales and product efficacy.
• Investors are considering AbbVie as a favorable investment option, undeterred by some doubts from financial analysts, given the company's strong track record and growth potential in key therapeutic areas.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?

ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

https://www.zacks.com/stock/news/2778719/should-you-buy-abbvie-stock-ahead-of-q3-earnings-report

Analysts Estimate AbbVie ( ABBV ) to Report a Decline in Earnings: What to Look Out for

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

https://www.zacks.com/stock/news/2776444/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings-what-to-look-out-for

Wall Street Analysts Think AbbVie ( ABBV ) Is a Good Investment: Is It?

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

https://www.zacks.com/stock/news/2776296/wall-street-analysts-think-abbvie-abbv-is-a-good-investment-is-it

AbbVie ( ABBV ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.

https://www.zacks.com/stock/news/2774600/abbvie-abbv-sees-a-more-significant-dip-than-broader-market-some-facts-to-know

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

https://www.zacks.com/stock/news/2774259/abbvie-up-more-than-30-in-6-months-how-to-play-the-stock

Trending Today

Gasoline ($GASOLINE) Commodity Forecast: Down 4.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 8.5% Today

XRP ($XRP) Crypto Forecast: Down 7.3% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.4% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.3% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.3% Today

International Paper Company ($IP) Stock Forecast: Down 12.4% Today

The Boeing Company ($BA) Stock Forecast: Down 6.2% Today

Roblox Corp ($RBLX) Stock Forecast: Down 16.0% Today

Altria Group Inc. ($MO) Stock Forecast: Down 7.8% Today

AbbVie Inc. Price History

04.03.2025 - ABBV Stock was down 5.2%

• The stock has seen a 16% rise year to date, indicating a positive trend overall.
• Unusual options activity today showed investors taking a bearish stance on AbbVie, possibly contributing to the bearish movement.
• Despite this, deep-pocketed investors have recently adopted a bullish approach towards AbbVie, suggesting conflicting sentiments in the market.
• The overall market sentiment seems mixed, with potential profit-taking by some investors and optimism about the company's future growth prospects.

28.09.2025 - ABBV Stock was up 0.0%

• AbbVie's recent market upturn is linked to positive market expectations for its upcoming Q3 earnings, with a particular focus on the growth of Skyrizi and Rinvoq.
• Market sentiment remains optimistic about AbbVie's future prospects despite analyst predictions of an earnings decrease, driven by the success of its leading drugs.
• Although the stock saw a slight decline compared to the overall market recently, the company has demonstrated significant growth of over 30% in the last six months, led by robust sales and product efficacy.
• Investors are considering AbbVie as a favorable investment option, undeterred by some doubts from financial analysts, given the company's strong track record and growth potential in key therapeutic areas.

12.04.2025 - ABBV Stock was up 5.4%

• Despite ongoing legal issues involving Cerevel Therapeutics Holdings, Inc. (linked to ABBV), AbbVie's stock remained unaffected, demonstrating investor confidence in the company's strength.
• Representative Marjorie Taylor Greene's significant acquisition of AbbVie shares likely played a role in enhancing market sentiment and contributing to the stock's positive movement.
• Investor focus appears to be primarily on AbbVie's performance and growth potential within the pharmaceutical sector, overshadowing the legal troubles of other related companies.
• The market's favorable response to the insider trading news and the overall bullish performance indicates investor optimism regarding AbbVie's future, despite legal uncertainties surrounding associated firms.

12.04.2025 - ABBV Stock was up 5.2%

• Uncommon options behavior indicated a positive outlook on AbbVie, attracting investor attention and contributing to the bullish trend.
• Reports of substantial AbbVie stock acquisitions by legislators may have boosted confidence in the company's future, driving up buying interest.
• Despite ongoing legal challenges, the positive publicity surrounding influential individuals investing in AbbVie likely overshadowed any potential negativity, pushing the stock price up.
• The optimistic options activity and significant stock acquisitions by government officials probably fostered a favorable outlook on AbbVie, prompting the bullish movement in the market.

15.04.2025 - ABBV Stock was down 5.0%

• The FDA fast-tracking AbbVie's new lung cancer therapy, Emrelis, may have sparked concerns among investors regarding the company's ability to meet high expectations, leading to profit-taking and a bearish trend.
• Unusual options activity indicating a bullish stance possibly initially boosted the stock, but the subsequent decline could suggest a shift in sentiment or profit realization by investors.
• The class action lawsuit against Cerevel Therapeutics Holdings, Inc., a company linked to AbbVie, likely created uncertainty and negative sentiment around AbbVie, contributing to the bearish movement.
• Representative Jared Moskowitz's significant purchase of AbbVie stock may have been viewed as a positive sign initially, but the overall market sentiment possibly overshadowed this, resulting in the bearish movement.

14.04.2025 - ABBV Stock was down 5.1%

• The bearish movement in AbbVie's stock price today could be attributed to profit-taking by investors after a recent increase in the stock value over the past month and year.
• The unusual options activity showing a bullish stance on AbbVie might indicate conflicting sentiments among investors, leading to increased volatility and potential sell-offs.
• The news of a Congressional report revealing a purchase of AbbVie stock by Representative Jared Moskowitz could have influenced market sentiment, but the overall impact on the stock price remains uncertain.
• The class action lawsuit notification against Cerevel Therapeutics Holdings, Inc. (ABBV) could have created negative sentiment around the pharmaceutical sector, impacting AbbVie's stock price negatively.

31.00.2025 - ABBV Stock was up 6.1%

• AbbVie's strong bullish movement today is linked to its Q4 earnings and sales performance surpassing expectations and an increased sales forecast for key drugs like Skyrizi and Rinvoq.
• The market reacted positively to AbbVie's revenue growth, particularly due to the success of newer immunology drugs that offset the decline in Humira sales.
• Investor confidence in AbbVie's future appears high, evident in the company's market outperformance over the past 5 years and the raised revenue forecast for key drugs.
• AbbVie's focus on innovative drugs and robust financial performance have been key drivers of its bullish movement today, reflecting investor confidence in the company's growth trajectory.

06.04.2025 - ABBV Stock was down 5.1%

• A class action securities lawsuit involving ABBV and Cerevel Therapeutics Holdings, Inc. has raised concerns among investors about potential legal risks and financial implications for AbbVie.
• AbbVie was mentioned in a program alongside Netflix and Sherwin-Williams, possibly leading to comparisons in performance and highlighting any weaknesses or challenges faced by AbbVie.
• The bearish movement in AbbVie's stock may be a reaction to negative sentiment in the pharmaceutical sector or specific company-related issues.

12.05.2025 - ABBV Stock was down 2.4%

• Despite positive FDA approval for Mavyret in pediatric patients with Hepatitis C and a significant purchase of AbbVie stock by Rep. Robert Bresnahan, the stock experienced a bearish movement.
• The market may have reacted negatively to concerns about AbbVie's ability to offset the sales drop post-U.S. patent loss of Humira, despite the expected growth from Skyrizi and Rinvoq.
• The overall market dip could have also contributed to AbbVie's bearish movement, as seen in the increase in stock price despite the market slip.
• Investors might be cautious about the company's future revenue streams and competitive positioning in the pharmaceutical industry, leading to the bearish trend in AbbVie's stock price.

01.09.2025 - ABBV Stock was up 6.3%

• The bullish trend in AbbVie's stock is linked to the company's announcement about seeking FDA approval for tavapadon, a potential treatment for Parkinson's disease. This development signifies advancement in the company's pipeline and hints at possible future revenue growth.
• While some investors showed bearish options activity, this viewpoint may be a short-term reaction, influenced by market fluctuations or individual strategies, rather than reflecting the overall optimistic outlook for AbbVie.
• AbbVie's shift beyond its successful drug Humira, with promising products like Skyrizi and Rinvoq, alongside its expansion into oncology and neuroscience fields, is likely instilling investor confidence and spurring the positive momentum in the stock.

01.09.2025 - ABBV Stock was up 5.5%

• AbbVie's upward movement is linked to its recent FDA filing for tavapadon, a potential treatment for Parkinson's disease. This development has instilled optimism among investors regarding the drug's potential success and its future impact on AbbVie's revenues.
• Options activity suggesting a bearish outlook on AbbVie may be due to profit-taking or hedging strategies among some investors. However, this activity has not significantly affected the overall market sentiment towards the stock.
• AbbVie's efforts to diversify its product portfolio beyond Humira, its blockbuster drug, with candidates like Skyrizi and Rinvoq in the development pipeline, have contributed to positive expectations for the company's growth prospects. This has further strengthened investor confidence in AbbVie's stock.

31.06.2025 - ABBV Stock was down 0.2%

• AbbVie reported strong Q2 sales growth and raised its 2025 earnings outlook, but the stock faced downward pressure.
• Market reaction to the company missing EPS estimates despite exceeding sales expectations may be a factor.
• Concerns about the potential impact of Humira's future decline on revenue growth, despite growth in Skyrizi and Rinvoq, are looming.
• AbbVie's stock movement may have been influenced by the overall performance of the pharmaceutical industry, with upcoming earnings releases from other key players like MRK, AZN, BMY, and MRNA.